Pathogenic role of serpin B3-positive neutrophils in reinforcing thrombus stiffening during ischemic stroke

Read full text
Authors: Jiankun Zang, Aijun Lu, Bing Yang, Na Tan, Qihuan Liu, Liping Wei, Ying Liang, Sijie Zhou, Zefeng Tan, Xiufeng Xin, Shenwen He, Panwen Wu
+6 more Yufeng Li, Zhifeng Xu, Xuanlin Su, Hongcheng Mai, Anding Xu, Dan Lu
Cited by: 2
References: 43

Abstract

ABSTRACT: The contribution of immune cells to thrombus architecture and mechanical properties in acute ischemic stroke (AIS) remains poorly understood. Using 3-dimensional imaging and multiplex staining, we mapped immune cells in human stroke thrombi and identified neutrophils as the dominant population. Analysis of 19 thrombi confirmed their positive correlation with collagen, increased stiffness, and poorer clinical outcomes. To preserve spatial context, we developed a laser capture-based proteomic workflow and analyzed thrombus neutrophils from 34 patients with AIS stratified by 90-day outcomes, followed by validation in an independent cohort of 22 patients. Proteomic analysis revealed serpin B3 as a neutrophil-enriched protein strongly correlated with poor prognosis. In murine models of ferric chloride-induced carotid artery thrombosis and middle cerebral artery occlusion, experiments using wild-type, neutrophil-depleted, and Serpinb3a knockout mice demonstrated that neutrophil-derived serpin B3 promotes early thrombus formation, enhances collagen deposition, and contributes to progressive thrombus stiffening. Mechanistically, serpin B3 secreted by neutrophils amplifies thrombus stiffness through upregulation of transforming growth factor β1, neutrophil extracellular traps, and COL1A1. Targeted Serpinb3a knockdown delayed vascular occlusion, improved thrombolysis efficiency, and resulted in better neurological recovery. Collectively, these findings identify a neutrophil-driven mechanism underlying thrombus stiffening and establish SERPINB3 as both a prognostic biomarker and a promising therapeutic target in AIS. This project has been registered with the Chinese Clinical Trial Registration Platform (https://www.chictr.org.cn/index.html) and has successfully passed the review process (registration number: ChiCTR2300077911).

Fields of Study & Subjects

Neutrophil Myeloperoxidase and Oxidative Mechanisms Acute Ischemic Stroke Management Neuroinflammation and Neurodegeneration Mechanisms

Publication details

Journal / source
Blood
Publisher
American Society of Hematology
Volume
147
Issue
25
Pages
3086–3101
Publication date
3 March 2026
Language
EN